Working in concert: radiology, pathology, and gynecologic oncology applications of the 2023 FIGO updates in endometrial cancer staging.

Wei Li, Tannaz Rajabi, Natalia Yanchenko, Jamie Linn McDowell, Ashlee L Smith, Sharlin Varghese, Akshya Gupta

Abstract readReview

In one paragraph

Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei LiUniversity of Rochester Medical Center, Rochester, USA. weil485@gmail.com.

Tannaz RajabiUniversity of Rochester Medical Center, Rochester, USA.

Natalia YanchenkoDepartment of Pathology, University of Rochester Medical Center, Rochester, USA.

Jamie Linn McDowellDepartment of Pathology, University of Rochester Medical Center, Rochester, USA.

Ashlee L SmithDepartment of Obstetrics & Gynecology, University of Rochester Medical Center, Rochester, USA.

Sharlin VargheseDepartment of Obstetrics & Gynecology, University of Rochester Medical Center, Rochester, USA.

Akshya GuptaDepartment of Imaging Sciences, University of Rochester Medical Center, Rochester, USA. Akshya_Gupta@urmc.rochester.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2023 FIGO staging update for endometrial cancer moves beyond anatomy to integrate histology and molecular classification. This review outlines the new framework, illustrates its application through radiologic-pathologic case vignettes, and highlights how multidisciplinary input guides staging and therapy. Major revisions include separate substages for aggressive histologies, depth-based divisions incorporating LVSI, and molecularly driven categories such as POLE-abnormal and p53-abnormal tumors. Although these refinements sharpen prognostic accuracy, unequal access to advanced testing and interpretive variability remain obstacles to uniform implementation.

Indexed as

Endometrial NeoplasmsFemaleHumansNeoplasm StagingCancer stagingCross-sectional imagingEndometrial cancerGynecologic oncologyLymphovascular space invasionMolecular classification

Identifiers

PMID41774132

DOI10.1016/j.suronc.2021.101566

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.